Mesenchymal stromal cells, from indifferent spectators to principal actors. Are we going to witness a revolution in the scenario of allograft and immune-mediated disorders?

Haematologica

Volumn 92, Issue 7, 2007, Pages 872-877

  Locatetti, Franco ^a   Maccario, Rita ^a   Frassoni, Francesco ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; B7 ANTIGEN; CD14 ANTIGEN; CD19 ANTIGEN; CD34 ANTIGEN; CD40 ANTIGEN; CD45 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ENDOGLIN; INTERLEUKIN 10; MYELOABLATIVE AGENT; NATURAL KILLER CELL RECEPTOR; TELOMERASE REVERSE TRANSCRIPTASE; THY 1 ANTIGEN; VASCULOTROPIN RECEPTOR 2;

ALLOGRAFT; AMYOTROPHIC LATERAL SCLEROSIS; AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOTOXICITY; EDITORIAL; ENZYME ACTIVITY; FLUORESCENCE IN SITU HYBRIDIZATION; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA SYSTEM; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; IMMUNOPATHOLOGY; MAJOR HISTOCOMPATIBILITY COMPLEX; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MYELOABLATIVE CONDITIONING; NATURAL KILLER T CELL; NEUROPROTECTION; NONHUMAN; NONOBESE DIABETIC MOUSE; PERIPHERAL BLOOD MONONUCLEAR CELL; RECEPTOR UPREGULATION; REGULATORY T LYMPHOCYTE; SCID MOUSE; SPINAL CORD INJURY; STROKE; STROMA CELL; ALLOTRANSPLANTATION; ANIMAL; GRAFT SURVIVAL; IMMUNOLOGY; METHODOLOGY; NOTE; T LYMPHOCYTE;

ANIMALS; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; STROMAL CELLS; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 34548778064     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11479     Document Type: Editorial

References (60)

1. Prevosto C, Zancolli M, Canevali P, Zocchi MR, Poggi A. Generation of CD4+ or CD8+ regulatory cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica 2007;92:881-8
2. Shi M, Li J, Liao L, Chen B, Li B, Chen L, Jia H, Zhao RC. Regulation of CXCR4 expression in human mesenchymal stem cell by cytokine treatment: role in homing efficiency in NOD/SCID mice. Haematologica 2007;92:897-904.
3. Puontos I, Jones E, Tzioupis C, McGonagle D, Giannoudis PV. Growing bone and cartilage. Role of mesenchymal stem cells. J Bone Joint Surg Br 2006;88:421-6.
4. Quarto R, Mastrogiacomo M, Cancedda R, Kutepov SM, Mukhacev V, Lavroukov A, et al. Repair of large bone defects with the use of autologous bone marrow stromal cells. N Engl J Med 2001;344:385-6.
5. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002;30:42-8.
6. Uccelli A, Pistoia V, Moretta L. Mesenchymal stem cells: a new strategy for immunosuppression? Trends Immunol 2007, 28:219-26.
7. Le Blanc K, Ringden O. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005;11:321-34.
8. Le Blanc K, Rasmusson I, Sundberg B, Götherström C, Hassan M, Uzunel M, et al. Treatment of severe graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004;363:1439-41.
9. Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, et al. Bone marrow mesenchymal stem cells inhibit the response of naïve and memory antigen-specific T cells to their cognate peptide. Blood 2003;101:3722-9.
10. Aggarwal S, Pittinger MF. Human mesenchymal stem cells modulate alloantigen immune cell responses. Blood 2005;105:1815-22.
11. Maccario R, Podestà M, Moretta A, Cometa A, Comoli P, Montagna D, et al. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 2005;90:516-25.
12. Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, et al. Human mesenchymal stem cells modulate B cell functions. Blood 2006; 107:367-72.
13. Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 1968;6:230-47.
14. Prockop DJ. Marrow stromal cells as stem cells for non-hematopoietic tissues. Science 1997;276:71-4.
15. Dexter TM, Moore MAS. In vitro duplication and "cure" of haemopoietic defects in genetically anaemic mice. Nature 1977;269:412-4.
16. Dexter TM, Allen TD, Lajtha LG. Conditions controlling the proliferation of haemopoietic stem cells in vitro. J. Cell. Physiol 1977;91:335-44.
17. Deans RJ, Moseley AB. Mesenchymal stem cells: Biology and potential clinical uses. Exp Hematol 2000; 28: 875-84.
18. Muller-Sieburg CE, Deryugina E. The stromal cells' guide to the stem cell universe. Stem Cells 1995;13:477-86.
19. Zhang J, Niu C, Ye L, Huang H, He X, Tong WG, et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 2003;425:836-41.
20. Wilson A, Trumpp A. Bone-marrow haematopoietic-stem-cell niches. Nat Rev Immunol 2006;6:93-106.
21. Ducy P, Schinke T, Karsenty G. The osteoblast: a sophisticated fibroblast under central surveillance. Science 2000;289:1501-4.
22. Erices A, Conget P, Minguell JJ. Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol 2000;109:235-42.
23. Noort WA, Kruisselbrink AB, in't Anker PS, Kruger M, van Bezooijen RL, de Paus RA, et al. Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived CD34+ cells in NOD/SCID mice. Exp Hematol 2002; 30:870-8.
24. Le Blanc K, Pittenger M. Mesenchymal stem cells: progress toward promise. Cytotherapy 2005;7:36-45.
25. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-7.
26. Bianco P, Gehron Robey P. Marrow stromal stem cells. J Clin Invest 2000;105:1663-8.
27. in't Anker PS, Noort WA, Kruisselbrink AB, Scherjon SA, Beekhuizen W, Willemze R, et al. Nonexpanded primary lung and bone marrow-derived mesenchymal cells promote the engraftment of umbilical cord blood-derived CD34+ cells in NOD/SCID mice. Exp Hematol 2003;31:881-9.
28. Almeida-Porada G, Flake AW, Glimp HA, Zanjani ED. Cotransplantation of stroma results in enhancement of engraftment and early expression of donor hematopoietic stem cells in utero. Exp Hematol 1999; 27:1569-75.
29. Koç ON, Gerson SL, Cooper BW, Dyhouse SM, Haynesworth SE, Caplan AI, et al. Rapid hematopoietic recovery after co-infusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000;18:307-16.
30. Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK, et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005;11:389-98.
31. Horwitz EM, Prockop DJ, Fitzpatrick LA, Koo WW, Gordon PL, Neel M, et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999;5:309-13.
32. Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, McNall RY, et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci USA 2002; 99:8932-7.
33. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or non specific mitogenic stimuli. Blood 2002;99:3838-43.
34. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003; 57:11-20.
35. Maccario R, Moretta A, Cometa A, Podestà M, Montagna D, Comoli P, et al. Human mesenchymal stem cells and cyclosporin-A exert a synergistic suppressive effect on in vitro activation of alloantigen-specific cytotoxic lymphocytes. Biol Blood Marrow Transplant 2005;11:1031-2.
36. Le Blanc K, Ringden O. Mesenchymal stem cells: properties and role in clinical bone marrow transplantation. Curr Opin Immunol 2006;18:586-91.
37. Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringden O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003;10:890-6.
38. Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EG, Willemze R, Fibbe WE. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a non-myeloablative setting. Blood 2006;108:2114-20.
39. Eliopoulos N, Stagg J, Lejeune L, Pommey S, Galipeau J. Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. Blood 2005;106:4057-65.
40. Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 2006;107:1484-90.
41. Rasmusson I, Ringden O, Sundberg B, Le Blanc K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003;76:1208-13.
42. Beyth S, Borovsky Z, Mevorach D, Liebergall M, Gazit Z, Asian H, et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T cell unresponsiveness. Blood 2005;105:2214-9.
43. Strobl H, Knapp W. TGF-b1 regulation of dendritic cells. Microbes Infect 1999; 1:1283-91.
44. Bernardo ME, Avanzini MA, Perotti C, Cometa AM, Moretta A, Lenta E, et al. Optimization or in vitro expansion of human multipotent mesenchymal stromal cells for cell-therapy approaches: further insights in the search for a fetal calf serum substitute. J Cell Physiol 2007;211:121-30.
45. Ringden O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lonnies H, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease, Transplantation 2006;81:1390-7.
46. Le Blanc K, Frassoni F. Ball L, Lanino E, Sundberg B, Lonnies L, et al. Mesenchymal stem cells for treatment of severe acute graft-versus-host disease, Blood 2006;108 Suppl 1:226a[abstract].
47. Sudres M, Norol F, Trenado A, Grégoire S, Charlotte F, Levacher B, et al. Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. J Immunol 2006;176:7761-7.
48. Giordano A, Galderisi U, Marino IR. From the laboratory bench to the patient's bedside: An update on clinical trials with mesenchymal stem cells. J Cell Physiol 2007; 211:27-35.
49. Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Gerdoni E, et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005;106:1755-61.
50. Hofstetter CP, Schwarz EJ, Hess D, Widenfalk J, El Manira A, Prockop DJ, et al. Marrow stromal cells form guiding strands in the injured spinal cord and promote recovery. Proc Natl Acad Sci USA 2002; 99:2199-204.
51. Chopp M., Li Y. Treatment of neural injury with marrow stromal cells. Lancet Neurol 2002;1:92-100.
52. Mazzini L, Mareschi K, Ferrero I, Vassallo E, Oliveri G, Boccaletti R, et al. Autologous mesenchymal stem cells: clinical applications in amyotrophic lateral sclerosis, Neurol Res 2006; 28:523-6.
53. Rubio D, Garcia-Castro J, Martín MC, de la Fuente R, Cigudosa JC, Lloyd AC, et al. Spontaneous human adult stem cell transformation. Cancer Res 2005;65:3035-9.
54. Miura M, Miura Y, Padilla-Nash HM, Molinolo AA, Fu B, Patel V, et al. Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. Stem Cells 2006;24:1095-103.
55. Bernardo ME, Zaffaroni N, Novara F, Cometa AM, Avanzini MA, Moretta A, et al. Human bone marrow-derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res
56. Caterson EJ, Nesti LJ, Danielson KJ Tuan RS. Human marrow derived mesenchymal progenitor cells: isolation culture, expansion and analysis of differentiation. Mol Biotechnol 2002;20:245-56.
57. Sotiropoulou PA, Perez SA, Salagianni M, Baxevanis CN, Papamichail M. Characterization of the optimal culture conditions for clinical scale production of human mesenchymal stem cells. Stem Cells 2006;24:462-71.
58. Gregory CA, Reyes E, Whitney MJ, Spees JL. Enhanced engraftment of mesenchymal stem cells in a cutaneous wound model by culture in allogeneic species-specific serum and administration in fibrin constructs. Stem Cells 2006;24:2232-43.
59. Spees JL, Gregory CA, Singh H, Tucker HA, Peister A, Lynch PJ, et al. Internalized antigens must be removed to prepare hypo-immunogenic mesenchymal stem cells for cell and gene therapy. Mol Ther 2004;9:747-56.
60. Doucet C, Ernou I, Zhang Y, Llense JR, Begot L, Holy X, Lataillade JJ. Platelet lysates promote mesenchymal stem cell expansion: a safety substitute for animal serum in cell-based therapy applications. J Cell Physiol 2005;205:228-36.